Onconetix, Inc. Liabilities, Fair Value Adjustment
Onconetix, Inc. (ONCO) reported Liabilities, Fair Value Adjustment of $1.21 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:LiabilitiesFairValueAdjustment · last filed 2026-08-13
- Onconetix, Inc. liabilities, fair value adjustment for the quarter ending 2026-06-30 was -$400.00.
- Onconetix, Inc. liabilities, fair value adjustment for the quarter ending 2026-03-31 was $1.61K.
- Onconetix, Inc. liabilities, fair value adjustment for the quarter ending 2025-12-31 was $26.56K, a 97.81% decline year-over-year.
- Onconetix, Inc. liabilities, fair value adjustment for the quarter ending 2025-09-30 was -$36.00.
- Onconetix, Inc. liabilities, fair value adjustment for fiscal 2025 was $16.50K, a 98.68% decline from fiscal 2024.
- Onconetix, Inc. liabilities, fair value adjustment for fiscal 2024 was $1.25M.
- Onconetix, Inc. liabilities, fair value adjustment for fiscal 2023 was -$91.97K, a 249.76% decline from fiscal 2022.
- Onconetix, Inc. liabilities, fair value adjustment for fiscal 2022 was $61.41K.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$400.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.21K 10-Q · filed 2026-08-13 | $27.77K derived: sum of 3 quarters · filed 2026-08-13 | $27.73K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.61K 10-Q · filed 2026-05-13 | $28.17K derived: sum of 2 quarters · filed 2026-05-13 | $28.14K derived: sum of 3 quarters · filed 2026-05-13 | $27.91K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $26.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $26.52K derived: sum of 2 quarters · filed 2026-03-13 | $26.29K derived: sum of 3 quarters · filed 2026-08-13 | $16.50K 10-K · filed 2026-03-13 |
| 2025-09-30 | -$36.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$265.00 derived: sum of 2 quarters · filed 2026-08-13 | -$10.06K 10-Q · filed 2025-11-13 | $1.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$229.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$10.02K 10-Q · filed 2026-08-13 | $1.20M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$9.79K 10-Q · filed 2026-05-13 | $1.20M derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.25M 10-K · filed 2026-03-13 | ||
| 2024-09-30 | $35.73K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $7.82K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | -$91.91K derived: sum of 2 quarters · filed 2025-06-02 | -$93.58K derived: sum of 3 quarters · filed 2025-06-02 | -$91.97K 10-K · filed 2025-06-02 |
| 2023-09-30 | -$99.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | -$101.40K derived: sum of 2 quarters · filed 2024-12-10 | -$99.79K 10-Q · filed 2024-12-10 | |
| 2023-06-30 | -$1.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | -$59.00 10-Q · filed 2024-08-29 | ||
| 2023-03-31 | $1.61K 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | $61.41K 10-K · filed 2024-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |